Abstract
All-trans retinoic acid was evaluated in metastatic measurable non-small cell lung cancer. All-trans retinoic acid was given at 175 mg/m2 orally on a daily basis. Twenty-eight patients (median age 58, 16 males, 12 women) had an ECOG performance status of 0 (26 patients) and 1 (two patients). Sixteen of the 28 had no weight loss. Eleven had between 5 and 10% and only one had greater than 10% weight loss at time of entry. Toxicities included cutaneous (cheletis 25/28), fatigue (10/28), myalgias/anthralgias (9/28), and headache (17/28). Alterations in triglycerides and hepatic transaminases were noted in a majority of patients. Two partial responses occurred in patients with adenocarcinoma. Both responses were 7 months in duration. Activity of all-trans retinoic acid in metastatic non-small cell lung cancer is minimal, but due to its low toxicity profile it should be tested in setting with other agents.
| Original language | English |
|---|---|
| Pages (from-to) | S55-S58 |
| Journal | Leukemia |
| Volume | 8 Suppl 3 |
| Issue number | SUPPL. 3 |
| State | Published - 1994 |
Keywords
- Adenocarcinoma/drug therapy
- Adult
- Aged
- Antineoplastic Agents/administration & dosage
- Carcinoma, Non-Small-Cell Lung/drug therapy
- Drug Administration Schedule
- Female
- Humans
- Lung Neoplasms/drug therapy
- Male
- Middle Aged
- Survival Analysis
- Treatment Outcome
- Tretinoin/administration & dosage
